TI AND FOR 1 11:10 THE HD imantsu With the recent rise in the utility segment valuations as investors prepare for the strong potential of lower competitive interest rates, CMS Energy Co (NYSE:CMS) stock price has been strong. This has led to an overabundance of "Hold" recommendations for CMS stock. However, for long-term investors, CMS should be viewed as a highquality selection, both in earnings and dividend production and, more importantly, in its supportive regulatory background. I do not own the common ...

Core Insights - Abeona Therapeutics announced that the Centers for Medicare and Medicaid Services (CMS) has granted a product-specific procedure code ICD-10-PCS for prademagene zamikeracel (pz-cel), an investigational gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) [1] - CMS assigned Medicare reimbursement for pz-cel to Pre-Major Diagnostic Category, Medicare Severity Diagnosis Related Group 018, which is among the highest reimbursement levels for cell and gene therapies, effective October 1, 2024 [2] - The Chief Commercial Officer of Abeona expressed confidence in securing access and reimbursement for RDEB patients following favorable Medicare decisions and positive feedback from commercial payers [3] Product Overview - Prademagene zamikeracel (pz-cel) is an autologous cell-based gene therapy designed to treat RDEB, a rare connective tissue disorder caused by a defect in the COL7A1 gene [4] - Pz-cel aims to incorporate the functional COL7A1 gene into a patient's skin cells, enabling long-term gene expression and facilitating wound healing [4] - The pivotal Phase 3 VIITAL™ study evaluated pz-cel's efficacy, safety, and tolerability in 43 large chronic wound pairs among 11 subjects with RDEB [4] Company Background - Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases [5] - The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, which supports the production of pz-cel for clinical trials and potential commercial use [5] - Abeona's development portfolio includes AAV-based gene therapies for ophthalmic diseases, utilizing next-generation AAV capsids to improve treatment efficacy [5]

Multiple AI-powered features and seamless CMS integration influence Sitefinity Insight's status as a RealCDP™ BURLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Progress (Nasdaq: PRGS), the trusted provider of AI-powered infrastructure software, today announced that Progress® Sitefinity Insight® customer data platform (CDP) has been certified by the Customer Data Platform (CDP) Institute as a RealCDP™ for meeting specific standards and capabilities that are essential for managing and utilizing customer da ...

NorthStar Clean Energy and General Motors launch Newport Solar to help power GM facilities ANN ARBOR, Mich., Aug. 7, 2024 /PRNewswire/ -- NorthStar Clean Energy proudly announces the official opening of Newport Solar, a 180 MW project designed to source renewable electricity for General Motors' operations in the Midcontinent Independent System Operator (MISO) territory including Lansing Delta Township Assembly and Lansing Grand River Assembly in Michigan, as well as Wentzville Assembly in Missouri, which un ...

. ● . Therma Bright Receives Positive Notification from U.S. DHHS's Centers for Medicare & Medicaid (CMS) Company anticipates CMS permanent CPT(R) and HCPCS codes in the coming days August 01, 2024 7:13 AM EDT | Source: Therma Bright Inc. Toronto, Ontario--(Newsfile Corp. - August 1, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to provi ...

CMS Energy Corporation (NYSE:CMS) Q2 2024 Results Conference Call July 25, 2024 9:30 AM ET Company Participants Jason Shore - Treasurer & Vice President, Finance & Investor Relations Garrick Rochow - President & Chief Executive Officer Rejji Hayes - Executive Vice President & Chief Financial Officer Conference Call Participants Jeremy Tonet - JPMorgan Shahriar Pourreza - Guggenheim Partners Michael Sullivan - Wolfe Andrew Weisel - Scotiabank Durgesh Chopra - Evercore Travis Miller - Morningstar, Inc. Nick C ...

| --- | --- | --- | --- | |------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------| | | | | | | Indicate by check ma ...

CMS Energy Corporation (CMS) reported second-quarter 2024 adjusted earnings per share (EPS) of 66 cents, which beat the Zacks Consensus Estimate of 63 cents by 4.8%. The bottom line, however, declined 12% from 75 cents reported in the prior-year quarter. Operating revenues totaled $1.61 billion, which lagged the Zacks Consensus Estimate of $1.69 billion by 5%. The top line, however, increased 3.3% on a year-over-year basis. Interest charges totaled $173 million, up 8.1% from that recorded a year ago. As of ...

CMS Energy (CMS) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for nonrecurring items. Over the last four quarters, the company has surpassed consensus EPS estimates three times. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the e ...

| --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------|-------|-------|------------------------|-------|-------------------------| | | | | Six Months \n6/30/24 | Ended | In Millions \n6/30/23 | | Beginning of Period Cash and Cash Equivalents, Including Restricted Amounts | | $ | 248 | $ | 182 | | Net cash provided by operating activities Net cash used in investing activities | | | 1,663 (1,246) | | 1,705 (2,079) | | Cash ...